Prothena Corporation plc - Ordinary Shares (PRTA) News
Filter PRTA News Items
PRTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRTA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PRTA News From Around the Web
Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.
Prothena Announces Board of Directors UpdateDUBLIN, December 30, 2024--Prothena announced that Oleg Nodelman will step down from Prothena’s Board of Directors to create time to focus on existing and new endeavors. |
We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's DiseaseProthena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage study. |
Prothena’s Parkinson’s study fails primary endpoint despite some successWhilst Prothena has said that it is still examining the late-stage treatment, the company confirmed it failed to meet its primary endpoint of slowing disease motor progression. |
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s DiseaseDUBLIN, December 19, 2024--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson’s disease. |
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in EuropeThe CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease. |
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in FocusPRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter. |
Prothena (PRTA) Reports Q3 Loss, Misses Revenue EstimatesProthena (PRTA) delivered earnings and revenue surprises of 6.78% and 53.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Prothena: Q3 Earnings SnapshotDUBLIN (AP) — Prothena Corp. PRTA) on Tuesday reported a loss of $59 million in its third quarter. The Dublin-based company said it had a loss of $1.10 per share. |